Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Lesogaberan

Criteria

Inclusion Criteria:

• Subject able to read and write US english and able to use electronic devices

• Subjects who have experienced GERD symptoms for at least six months

• Subjects currently taking a prescription or over-the-counter PPI medications for GERD

• Body Mass Index (BMI) 18.5-35.0, inclusive

Exclusion Criteria:

• Subjects that have not experienced any GERD symptoms improvement at all after PPI treatment

• Subjects who have any of the following conditions or diseases- Heart disease, Angina, Seizure disorders such as epilepsy, Congestive Heart Failure (CHF), Liver disease such as Cirrhosis or Hepatitis, Kidney disease, Lung disease or lung cancer, Cancer

• Prior surgery of the upper Gastrointestinal (GI) tract